{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:52:11Z","timestamp":1794009131846,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.esmoop.2024.103488","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T13:00:02Z","timestamp":1717592402000},"page":"103488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-5538","authenticated-orcid":false,"given":"A.","family":"Vogel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.M.","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Melisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Al Rajabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Paulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gallinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.-Y.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.V.","family":"Catenacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.F.","family":"Lihou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.K.","family":"Abou-Alfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.esmoop.2024.103488_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103488_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.24351","article-title":"Risk factors for cholangiocarcinoma","volume":"54","author":"Tyson","year":"2011","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103488_bib3","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/oncolo\/oyac150","article-title":"Temporal changes in cholangiocarcinoma incidence and mortality in the United States from 2001 to 2017","volume":"27","author":"Javle","year":"2022","journal-title":"Oncologist"},{"issue":"23","key":"10.1016\/j.esmoop.2024.103488_bib4","doi-asserted-by":"crossref","first-page":"744","DOI":"10.21037\/atm.2019.12.37","article-title":"Cholangiocarcinoma: anatomical location-dependent clinical, prognostic, and genetic disparities","volume":"7","author":"Hang","year":"2019","journal-title":"Ann Transl Med"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103488_bib5","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103488_bib6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.esmoop.2024.103488_bib7","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103488_bib8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103488_bib9","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2024.103488_bib10","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1200\/GO.20.00030","article-title":"Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma","volume":"6","author":"Kongpetch","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103488_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100641","article-title":"Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations","volume":"7","author":"Murugesan","year":"2022","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103488_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11523-022-00906-w","article-title":"Effect of FGFR2 alterations on overall and progression-free survival in patients receiving systemic therapy for intrahepatic cholangiocarcinoma","volume":"17","author":"Abou-Alfa","year":"2022","journal-title":"Target Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2024.103488_bib13","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.3390\/cancers13225681","article-title":"Biological significance and targeting of the FGFR axis in cancer","volume":"13","author":"Chioni","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2024.103488_bib14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-med-042921-024707","article-title":"FGFR2 inhibition in cholangiocarcinoma","volume":"74","author":"Vogel","year":"2023","journal-title":"Annu Rev Med"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103488_bib16","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/gutjnl-2011-301748","article-title":"Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update","volume":"61","author":"Khan","year":"2012","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103488_bib17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103488_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103488_bib19","series-title":"Full Prescribing Information","year":"2022"},{"key":"10.1016\/j.esmoop.2024.103488_bib20","series-title":"Full Prescribing Information","year":"2023"},{"key":"10.1016\/j.esmoop.2024.103488_bib21","series-title":"Biliary Tract Cancers","article-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)","year":"2024"},{"key":"10.1016\/j.esmoop.2024.103488_bib22","article-title":"Summary of Product Characteristics","year":"2023","journal-title":"S\u00f6dert\u00e4lje, Sweden: AstaZeneca AB"},{"key":"10.1016\/j.esmoop.2024.103488_bib23","article-title":"Summary of Product Characteristics","year":"2020","journal-title":"Haarlem, The Netherlands: Merck Sharp & Dohme B.V"},{"issue":"14","key":"10.1016\/j.esmoop.2024.103488_bib24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103488_bib25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103488_bib26","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"10391","key":"10.1016\/j.esmoop.2024.103488_bib27","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.103488_bib28","series-title":"Full Prescribing Information","year":"2022"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103488_bib29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103488_bib30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103488_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12876-016-0527-z","article-title":"Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics database","volume":"16","author":"Yao","year":"2016","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103488_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000517258","article-title":"Cholangiocarcinoma: an emerging target for molecular therapy","volume":"8","author":"Tsimafeyeu","year":"2021","journal-title":"Gastrointest Tumors"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103488_bib34","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: a systematic review","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103488_bib35","article-title":"Progression-free survival in patients with cholangiocarcinoma with or without FGF\/FGFR alterations: a FIGHT-202 post hoc analysis of prior systemic therapy response","volume":"6","author":"Bibeau","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103488_bib36","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2024.103488_bib37","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1200\/JCO.2022.40.4_suppl.430","article-title":"Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations","volume":"40","author":"Feng","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2024.103488_bib38","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2022.40.16_suppl.3007","article-title":"Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: interim analysis (IA) results","volume":"40","author":"Loriot","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103488_bib39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2024.103488_bib40","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/JCO.2023.41.16_suppl.4009","article-title":"Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors","volume":"41","author":"Borad","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103488_bib41","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.3390\/cancers12082190","article-title":"Molecular and immunological characterization of biliary tract cancers: a paradigm shift towards a personalized medicine","volume":"12","author":"Malenica","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"30","key":"10.1016\/j.esmoop.2024.103488_bib42","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Bekaii-Saab","year":"2020","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103488_bib43","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","article-title":"Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications","volume":"72","author":"Martin-Serrano","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.esmoop.2024.103488_bib44","doi-asserted-by":"crossref","first-page":"S1457","DOI":"10.1016\/j.annonc.2022.10.104","article-title":"68O Impact of mutation status on efficacy outcomes in TOPAZ-1: a phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (plus GC) in advanced biliary tract cancer (BTC)","volume":"33","author":"Valle","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103488_bib45","series-title":"Summary of Product Characteristics. Amsterdam, The Netherlands: Incyte Biosciences Distribution","year":"2022"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924012572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924012572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:10:20Z","timestamp":1729696220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924012572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2059702924012572"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103488","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103488","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103488"}}